|

Breast Cancer Clinical Trials in Phoenix, AZ

81 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Phase 3<1 mi
The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyPhase 3<1 mi
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.Phase 3<1 mi
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Phase 3<1 mi
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsN/A<1 mi
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing—<1 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3<1 mi
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPhase 2<1 mi
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerPhase 2<1 mi
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerPhase 2<1 mi
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN TrialsN/A<1 mi
Mobile Health for Adherence in Breast Cancer PatientsN/A<1 mi
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.Phase 3<1 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3<1 mi
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles—<1 mi
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic PainPhase 2<1 mi
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerPhase 3<1 mi
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerPhase 3<1 mi
E-Mindfulness Approaches for Living After Breast CancerPhase 3<1 mi
The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer SurvivorsN/A<1 mi
Breast Cancer, Reasoning, and Activity InterventionN/A<1 mi
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationPhase 3<1 mi
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerN/A<1 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 3<1 mi
Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening—<1 mi
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3<1 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3<1 mi
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Phase 3<1 mi
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/A<1 mi
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesPhase 1/2<1 mi
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsPhase 1/2<1 mi
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3<1 mi
Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast CancerN/A<1 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—<1 mi
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Phase 1/2<1 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—<1 mi
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialPhase 3<1 mi
Adaptive Symptom Self-Management Immunotherapy StudyN/A<1 mi
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform—<1 mi
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePhase 311 mi
Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer—11 mi
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With PembrolizumabPhase 1/211 mi
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid TumorsPhase 111 mi
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast CancerPhase 211 mi
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic TherapyN/A11 mi
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton TherapyPhase 311 mi
Low Dose Aspirin for the Prevention of Postpartum Related Breast CancerPhase 211 mi
Cancer Genetic Testing in Ethnic PopulationsN/A11 mi
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast CancerPhase 211 mi
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPhase 211 mi
The PREDICT Registry:—11 mi
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast CancerPhase 211 mi
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationPhase 311 mi
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing SurgeryPhase 211 mi
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067Phase 1/211 mi
Study of PF-07248144 in Advanced or Metastatic Solid TumorsPhase 211 mi
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H MutationPhase 111 mi
A Study of LY4170156 in Participants With Selected Advanced Solid TumorsPhase 111 mi
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)Phase 1/211 mi
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid MalignanciesPhase 111 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—11 mi
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 YearsPhase 411 mi
Phase IIIb Study of Ribociclib + ET in Early Breast CancerPhase 316 mi
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsPhase 316 mi
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseasePhase 317 mi
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Phase 317 mi
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Phase 317 mi
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerPhase 217 mi
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Phase 317 mi
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPhase 317 mi
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation—17 mi
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerPhase 118 mi
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerPhase 318 mi
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerPhase 318 mi
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast CancerPhase 1/218 mi
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic TherapyN/A18 mi
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerPhase 1/218 mi
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer—18 mi
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerPhase 318 mi
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationPhase 118 mi
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 ExpressionPhase 1/218 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.